Imaging and Dosing in Radioimmunotherapy with Yttrium 90 Ibritumomab Tiuxetan (Zevalin)

Seminars in Nuclear Medicine

Volumn 34, Issue 1 SUPPL.1, 2004, Pages 10-13

  Spies, Stewart M ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARCITUMOMAB TC 99M; CAPROMAB PENDETIDE IN 111; CEASCAN; CHELATING AGENT; IBRITUMOMAB TIUXETAN; INDIUM 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3 IN 111; ONCOSCINT; RITUXIMAB; TIUXETAN; UNCLASSIFIED DRUG;

BINDING SITE; BLOOD TOXICITY; DIAGNOSTIC IMAGING; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHADENOPATHY; NONHODGKIN LYMPHOMA; PREDICTION; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOIMMUNOTHERAPY; REVIEW; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 0842324899     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2003.11.004     Document Type: Article

References (15)

1. Potamianos S, Varvarigou AD, Archimandritis SC: Radioimmunoscintigraphy and radioimmunotherapy in cancer: Principles and application. Anticancer Res 20:925-48, 2000
2. Wiseman GA, White CA, Sparks RB, et al: Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 39:181-194, 2001
3. Lamb HM, Faulds D. Capromab pendetide. A review of its use as an imaging agent in prostate cancer. Drugs Aging 12:293-304, 1998
4. Pinkas L, Robins PD, Forstrom LA, et al: Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature. Nucl Med Commun 20:689-696, 1999
5. Leitha T, Walter R, Schlick W, et al: 99mTc-anti-CEA radioimmunoscintigraphy of lung adenocarcinoma. Chest 99: 14-19, 1991
6. Illidge TM, Johnson PW: The emerging role of radioimmunotherapy in haematological malignancies. Br J Haematol 108:679-688, 2000
7. Anderson KC, Bates MP, Slaughenhoupt BL, et al: Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63:1424-1433, 1984
8. Zelenetz AD: Radioimmunotherapy for lymphoma. Curr Opin Oncol 11:375-380, 1999
9. 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 5(suppl 10):3281s-3286s, 1999
10. Colcher D: Centralized radiolabeling of antibodies for radioimmunotherapy. J Nucl Med 39: 11S-13S, 1998
11. Wiseman GA, Leigh B, Erwin WD, et al: Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 94:1349-1357, 2002
12. Knox SJ, Goris ML, Trisler K, et al: Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2:457-470, 1996
13. Zevalin (ibritumomab tiuxetan) prescribing information. Cambridge, MA, Biogen Idec Inc, 2002
14. Biogen Idec imaging atlas. Cambridge, MA, Biogen Idec Inc, 2002
15. 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 27:766-777, 2000